Volume 6, Issue 1 (Multidisciplinary Cancer Investigation 2022)                   Multidiscip Cancer Investig 2022, 6(1): 1-7 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Moori M, Norouzian D, Yaghmaei P, Farahmand L. Effects of 1Hz 100mT electromagnetic field on apoptosis induction and Bax/Bcl-2 expression ratio in breast cancer cells. Multidiscip Cancer Investig. 2022; 6 (1) :1-7
URL: http://mcijournal.com/article-1-348-en.html
Abstract:   (266 Views)

Introduction: Breast cancer is the most common metastatic malignancy and the second leading cause of death in women. Recently, extremely low-frequency electromagnetic fields (ELF-EMFs) seem to modulate the rate of proliferation and enhance apoptosis and are considered as an emerging approach to cancer therapy. Despite recent success in the electromagnetic fields, the results are still neither definitive nor even contradictory.  
Methods: In this
udy, induction of apoptosis was considered as one of the possible mechanisms of ELF-EMFs on cancer inhibition. Brea cancer cell lines were exposed to a 1 Hz, 100mT ELF-EMF (2h/day) for five days. the apoptosis rare of both the exposure and sham exposure groups was determined by flow cytometry. The expression levels of Bax and Bcl-2 were evaluated by real-time PCR.
Results: The mRNA expression levels of Bax were increased; while the expression of Bcl-2 showed a decrease in MDA-MB231 cells exposed to 1Hz EMF compared with sham exposure. Moreover, the ratio of Bax/Bcl2 was significantly increased in comparison to the sham exposure. The increased Bax/Bcl-2 ratio induces cell apoptosis.
Conclusions: It is sugge
ed that ELF-EMF is a new adjuvant therapeutical method that may contribute to anti-cancer and cancer therapy research.

Full-Text [PDF 403 kb]   (161 Downloads)    
Type of Study: Original/Research Article | Subject: Other
Received: 2021/12/17 | Accepted: 2022/02/20 | ePublished: 2022/03/17

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb